TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Voluntary signing of an informed consent form (ICF)；

Males or females, aged 18-70 years (inclusive);

Subjects with advanced solid tumors confirmed by histology/cytology, have failed with standard treatment, or intolerant to standard treatment, or no standard treatment exists：1）Colorectal cancer：failed or intolerant to at least two lines of standard treatment.2）Non-small cell lung cancer：Absence of the following gene mutations (Epidermal Growth Factor Receptor[EGFR]、Anaplastic Lymphoma Kinase[ALK] 、 Proto-oncogene tyrosine-protein kinase 1[ROS1]) and having failed or intolerant to platinum-based chemotherapy and/or immunotherapy and/or anti-angiogenic therapy.3）Other advanced solid tumors：failed with standard treatment, or intolerant to standard treatment, or no standard treatment exist.

At least one measurable lesion (according to Response Evaluation Criteria in Solid Tumors[RECIST], version 1.1);